Jacob Leach serves as President and Chief Executive Officer of Dexcom, Inc., a leading innovator in continuous glucose monitoring (CGM) technology for diabetes management. With over 25 years of experience in the medical device and healthcare industries, Leach began his career at Medtronic, where he rose through the ranks to lead global product development for diabetes care solutions. His tenure there honed his expertise in regulatory affairs, clinical trials, and market expansion, culminating in the successful launch of several pivotal insulin delivery systems that improved patient outcomes worldwide. Before joining Dexcom in 2018 as Chief Operating Officer, Leach held executive roles at Abbott Laboratories, overseeing the diabetes division's transition to advanced sensor technologies. Under his leadership as COO, Dexcom achieved record revenue growth, expanded its global footprint to over 50 countries, and secured FDA approvals for next-generation CGM devices like the G7 system, which set new standards for accuracy and user-friendliness. Promoted to President and CEO in 2022, Leach has driven the company's market capitalization beyond $40 billion, fostering strategic partnerships with tech giants like Apple and Google to integrate CGM data into broader health ecosystems. Today, as CEO, Leach spearheads Dexcom's mission to make CGM accessible to millions, emphasizing innovation in real-time analytics and integration with insulin pumps. His visionary approach has not only propelled Dexcom to leadership in the diabetes technology space but also earned him accolades such as the Medical Device CEO of the Year from MedTech Dive. Leach's commitment to patient-centric innovation continues to transform diabetes care, positioning Dexcom at the forefront of personalized medicine.